Innate Pharma (XPAR:IPH) Days Payable : 0.00 (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Innate Pharma Days Payable?

Innate Pharma's average Accounts Payable for the six months ended in Dec. 2023 was €13.78 Mil. Innate Pharma's Cost of Goods Sold for the six months ended in Dec. 2023 was €0.00 Mil.

The historical rank and industry rank for Innate Pharma's Days Payable or its related term are showing as below:

During the past 13 years, Innate Pharma's highest Days Payable was 26289.75. The lowest was 151.87. And the median was 1993.63.

XPAR:IPH's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 148.53
* Ranked among companies with meaningful Days Payable only.

Innate Pharma's Days Payable stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).

Innate Pharma Days Payable Historical Data

The historical data trend for Innate Pharma's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innate Pharma Days Payable Chart

Innate Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

230.25

3,757.00

Innate Pharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Innate Pharma's Days Payable

For the Biotechnology subindustry, Innate Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innate Pharma's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innate Pharma's Days Payable distribution charts can be found below:

* The bar in red indicates where Innate Pharma's Days Payable falls into.

Innate Pharma Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Innate Pharma's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (13.656	+	8.561)	/	2 )	/	0	*	365
=	11.1085					/	0	*	365
=	N/A

Innate Pharma's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (18.991	+	8.561)	/	2 )	/	0	*	365 / 2
=	13.776					/	0	*	365 / 2
=	N/A

Innate Pharma Days Payable Related Terms

Thank you for viewing the detailed overview of Innate Pharma's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Innate Pharma (XPAR:IPH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (XPAR:IPH) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

IPHYF:USA IPHA:USA 0EVI:UK IDDA:Germany

Address

117, Avenue de Luminy, Marseille, FRA, 13009

Website

https://www.innate-pharma.com

Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, avdoralimab, and others.

Innate Pharma (XPAR:IPH) Headlines

No Headlines